Developer docs
API playgroundTry for free, no card

Search company profiles

Aureka Biotechnologies

Full company profile

uuid0000yk9

Namestring
Aureka Biotechnologies
Legal namestring
Aureka Biotechnologies, Inc.
Websiteurl
aurekabio.com
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLaguna Hills, United States
HQ citystring
Laguna Hills
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI antibody discovery, bispecific antibody engineering, generative protein design, antibody drug conjugates, high-throughput biologics screening
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-driven antibody therapeutics discovery
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharma business development and NewCo cooperation deals
TypeProfessional Services
Description

Revenue generated through business development agreements and NewCo cooperation arrangements with multiple multinational pharmaceutical companies. The company has achieved tens of millions of dollars in revenue via this motion. These are typically milestone-driven, partnership-based deals that monetize Aureka's platform output.

eu.36kr.com
2Internal pipeline licensing / asset out-licensing
TypeLicensing Royalties
Description

Aureka is developing eight proprietary antibody pipelines across cardiovascular metabolism, immunology and CNS disease areas. Future monetization expected through out-licensing of these proprietary assets to larger pharma partners, in addition to preparing two projects for clinical trials.

eu.36kr.com
3Reagent antibody discovery services
TypeProfessional Services
Description

Custom antibody discovery and engineering services for research reagent development, exemplified by the project with BD Biosciences to develop high-performance research reagents using Aureka's generative AI-empowered platform.

aurekabio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based / not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing, plans, or tiers disclosed. Engagement initiated via Contact Us form (General Inquiry, Partnering, Careers, Media Inquiry) at contact@aurekabio.com.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1AuraIDE™
Description

AI-driven antibody drug design platform developed by Aureka Biotechnologies for accelerating antibody therapeutic discovery.

eu.36kr.com
Core offering1 text field

Aureka Biotechnologies commercializes an integrated AI-driven antibody drug design platform — AuraIDE™ — that combines high-throughput synthetic biology (autonomous yeast-based hypermutation), single-cell microfluidic functional screening, and a geometric-aware protein language model with deep reinforcement learning in a closed-loop Generate-Test-Learn-Optimize cycle. The platform is delivered to multinational pharmaceutical and biotech clients via enterprise antibody discovery partnerships, NewCo cooperation agreements, and custom service engagements (e.g., the BD Biosciences reagent development project), and also underpins an internal pipeline of eight proprietary antibody therapeutics across cardiometabolic, immunology, and CNS disease areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Drug discovery timeline reduced from months to weeks
+4 more records
Product overview1 text field

Aureka Biotechnologies sells a unified, integrated tech-bio discovery platform (centered on the AuraIDE™ AI-driven antibody drug design platform) composed of three interlocking modules: (1) a High-Throughput Synthetic Biology / Autonomous Evolution engine that mines, synthesizes and characterizes therapeutic candidates at scale; (2) a proprietary Single-Cell Functional Screening platform based on droplet-based microfluidics that produces indexable per-cell data; and (3) a Protein Geometric Language Model and Deep Reinforcement Learning engine that drives the Generate–Test–Learn–Optimize loop. Together these modules power both Aureka's internal pipeline of cardiometabolic and inflammatory antibody therapeutics (including BsABs, ADCs and receptor agonists) and external offerings such as the Bispecific Antibody Discovery Pipeline and the Reagent Antibody Development Service (used in its BD Biosciences collaboration).

Product and service5 records
1AuraIDE™ AI-driven antibody drug design platform
CategoryCore AI platform
Description

Proprietary AI-driven antibody drug design and optimization platform combining large-scale multimodal data with generative AI for rational, multi-objective and de novo protein therapeutic design, including bispecific antibodies, ADCs, and candidates for challenging targets such as GPCRs.

2Bispecific Antibody (BsAB) Discovery Pipeline
CategoryAntibody discovery service
Description

High-throughput BsAB discovery service screening 1,000s to 100,000s of bispecific/multispecific variants in a single experiment; supports T-cell engagers (BiTEs), TCR mimics, soluble TCRs, bispecific/biparatopic ADCs, protein degraders (PROTABs), cytokine mimics, fusion proteins, and multi-subunit membrane receptor modulators.

3Reagent Antibody Development Service
CategoryCustom antibody development service
Description

Generative AI-empowered antibody discovery and engineering service used to develop high-performance research reagents, validated through the project with BD (Becton, Dickinson and Company).

4Pharma Antibody Discovery Partnerships and NewCo Cooperation
CategoryEnterprise collaboration / licensing
Description

Multi-year enterprise antibody discovery and NewCo cooperation engagements with multinational pharmaceutical companies that monetize Aureka's AuraIDE™ platform output via milestone-driven partnership deals.

5Internal Cardiometabolic, Immunology, and CNS Antibody Pipeline
CategoryInternal therapeutic pipeline / out-licensing
Description

Proprietary internal pipeline of eight differentiated antibody therapeutics targeting cardiovascular metabolism, immunology, and CNS disease areas, intended for out-licensing to larger pharma partners and clinical development (two projects targeted for clinical trials by end of 2026).

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCore Ecosystem PartnerTypeGTM or Marketing PartnerAnnounced on2025-12-04
Description

Aureka featured in Biocom California's Member Spotlight (December 4, 2025). Biocom is a California life-sciences industry association providing networking, partnering conferences (e.g., Global Life Science Partnering & Investor Conference), and member visibility.

2Dr. David W. Shen (Founder & CEO, Propeller Bio)
Strategic tierStrategic AdvisorTypeOthersAnnounced on2025-08-06
Description

Joined Aureka's Scientific Advisory Board (August 6, 2025). Dr. Shen brings experience in biopharmaceutical innovation, from scientific research to company building. He is Founder & CEO of Propeller Bio. His expertise will guide Aureka's mission to accelerate therapeutic discovery through AI and high-throughput biology.

aurekabio.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-09-10
Description

Co-presented in the ACRO Biosystems 'Building the Perfect Antibody-based Therapeutic' webinar (September 10, 2024) alongside Aureka Bio and ACRO Biosystems. Zymeworks presented on antibody engineering with AI-driven candidate selection optimization.

Strategic tierModerateTypeGTM or Marketing PartnerAnnounced on2024-09-10
Description

Co-presented the 'Building the Perfect Antibody-based Therapeutic' webinar (September 10, 2024) with Aureka Bio and Zymeworks. ACRO Biosystems covered precision in antibody conjugation and ADC manufacturing tools. Also co-organized the ACROConnect Workshop at World ADC San Diego 2024.

Strategic tierFlagship Strategic CustomerTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

Announced project (May 23, 2024) with BD, a leading global medical technology company, to harness Aureka's generative AI-empowered antibody discovery and engineering platform to develop high-performance research reagents for scientific research.

Strategic tierFlagship Ecosystem PartnerTypeTechnology or IntegrationAnnounced on2023-12-05
Description

Aureka joined NVIDIA Inception (announced December 4, 2023), a program that nurtures startups revolutionizing industries with AI. Benefits include access to advanced NVIDIA hardware and software, NVIDIA Deep Learning Institute credits, preferred pricing, and technological assistance to scale Aureka's AI-driven drug discovery efforts.

7Dr. Peter M. Tessier (Albert M. Mattocks Professor, University of Michigan)
Strategic tierStrategic AdvisorTypeOthersAnnounced on2023-10-19
Description

Joined Aureka Biotechnologies' Scientific Advisory Board (October 19, 2023). Dr. Tessier holds the Albert M. Mattocks Professorship in Pharmaceutical Sciences and Chemical Engineering at the University of Michigan and is internationally recognized for expertise in protein engineering, biopharmaceuticals, computational biology and drug discovery.

aurekabio.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BigHat Biosciences uses an AI-guided antibody design platform with high-throughput wet-lab characterization to engineer antibody candidates for pharma partners. Directly comparable in integrating machine learning with experimental data for next-generation antibody design.

TypeDirect peer
Description

Adagene is an AI-driven antibody discovery and development company using its Dynamic Precision Therapeutics platform to engineer antibody candidates against difficult oncology targets. Overlaps with Aureka in AI-driven antibody discovery and function-first design philosophy.

TypeBroad incumbent
Description

Insitro applies machine learning to pharma discovery with a focus on data-driven biology and partnerships with large pharma (Genentech, Eli Lilly). Comparable in spirit to Aureka as a data + AI + biology platform pursuing pharma BD deals, though focused on small-molecule and target discovery rather than antibodies.

TypeDirect peer
Description

Absci combines generative AI (zero-shot protein design) with high-throughput synthetic biology (soluency E. coli-based screening) to design and validate antibody therapeutics end-to-end. Closely parallel to Aureka's generative-AI-plus-wet-lab stack and pharma partnership GTM.

TypeDirect peer
Description

Generate Biomedicines is a generative AI biotech (founded by Flagship Pioneering) developing protein therapeutics de novo — directly paralleling Aureka's generative antibody design approach and pharma-partnered business model.

TypeEmerging player
Description

Xaira Therapeutics is a well-funded AI drug discovery startup (launched in 2024 with $1B) applying foundation models to protein design and small-molecule discovery. Comparable to Aureka in generative biology focus, though broader in scope and deeper-pocketed.

TypeEmerging player
Description

Cradle uses generative AI for protein engineering, with applications spanning enzymes and therapeutics. Comparable to Aureka in its protein language model + iterative wet-lab learning approach, but with broader end-markets beyond antibodies.

TypeDirect peer
Description

AbCellera operates a tech-bio platform for AI-driven antibody discovery, including its own wet-lab screening and a protein language model (like Aureka, it combines high-throughput biology with machine learning for therapeutic antibody generation). It is the most-cited comparable for Aureka's BD-and-pipeline business model.

9Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's protein-folding and AI capabilities to drug design. A broad incumbent whose capabilities overlap with Aureka's protein language model approach, with much greater capital and computational resources.

TypeDirect peer
Description

Adimab operates one of the most established antibody discovery platforms used by major pharma partners, with a focus on bispecifics and challenging targets. Although more traditional (less AI-native than Aureka), it is a direct competitor for the same pharma BD and bispecific discovery deals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aureka Biotechnologies

AI-driven antibody therapeutics discoveryaurekabio.com

Aureka Biotechnologies firmographics

Firmographics
Name
Aureka Biotechnologies
Legal name
Aureka Biotechnologies, Inc.
Website
https://aurekabio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Aureka Biotechnologies industry classification

Industry
Product category
AI-driven antibody therapeutics discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI antibody discovery
  • Bispecific antibody engineering
  • Generative protein design
  • Antibody drug conjugates
  • High-throughput biologics screening

Where Aureka Biotechnologies is headquartered

Location

Headquarters

HQ city
Laguna Hills
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aureka Biotechnologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharma business development and NewCo cooperation deals: Revenue generated through business development agreements and NewCo cooperation arrangements with multiple multinational pharmaceutical companies. The company has achieved tens of millions of dollars in revenue via this motion. These are typically milestone-driven, partnership-based deals that monetize Aureka's platform output.
  2. Internal pipeline licensing / asset out-licensing: Aureka is developing eight proprietary antibody pipelines across cardiovascular metabolism, immunology and CNS disease areas. Future monetization expected through out-licensing of these proprietary assets to larger pharma partners, in addition to preparing two projects for clinical trials.
  3. Reagent antibody discovery services: Custom antibody discovery and engineering services for research reagent development, exemplified by the project with BD Biosciences to develop high-performance research reagents using Aureka's generative AI-empowered platform.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based / not publicly disclosed

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Aureka Biotechnologies product offering

Product offering

Core offering

Aureka Biotechnologies commercializes an integrated AI-driven antibody drug design platform — AuraIDE™ — that combines high-throughput synthetic biology (autonomous yeast-based hypermutation), single-cell microfluidic functional screening, and a geometric-aware protein language model with deep reinforcement learning in a closed-loop Generate-Test-Learn-Optimize cycle. The platform is delivered to multinational pharmaceutical and biotech clients via enterprise antibody discovery partnerships, NewCo cooperation agreements, and custom service engagements (e.g., the BD Biosciences reagent development project), and also underpins an internal pipeline of eight proprietary antibody therapeutics across cardiometabolic, immunology, and CNS disease areas.

Product overview

Aureka Biotechnologies sells a unified, integrated tech-bio discovery platform (centered on the AuraIDE™ AI-driven antibody drug design platform) composed of three interlocking modules: (1) a High-Throughput Synthetic Biology / Autonomous Evolution engine that mines, synthesizes and characterizes therapeutic candidates at scale; (2) a proprietary Single-Cell Functional Screening platform based on droplet-based microfluidics that produces indexable per-cell data; and (3) a Protein Geometric Language Model and Deep Reinforcement Learning engine that drives the Generate–Test–Learn–Optimize loop. Together these modules power both Aureka's internal pipeline of cardiometabolic and inflammatory antibody therapeutics (including BsABs, ADCs and receptor agonists) and external offerings such as the Bispecific Antibody Discovery Pipeline and the Reagent Antibody Development Service (used in its BD Biosciences collaboration).

Differentiator

Problem solved

Functional benefit

Brands

  • AuraIDE™: AI-driven antibody drug design platform developed by Aureka Biotechnologies for accelerating antibody therapeutic discovery.

Products and services

  • AuraIDE™ AI-driven antibody drug design platform Proprietary AI-driven antibody drug design and optimization platform combining large-scale multimodal data with generative AI for rational, multi-objective and de novo protein therapeutic design, including bispecific antibodies, ADCs, and candidates for challenging targets such as GPCRs.
  • Bispecific Antibody (BsAB) Discovery Pipeline High-throughput BsAB discovery service screening 1,000s to 100,000s of bispecific/multispecific variants in a single experiment; supports T-cell engagers (BiTEs), TCR mimics, soluble TCRs, bispecific/biparatopic ADCs, protein degraders (PROTABs), cytokine mimics, fusion proteins, and multi-subunit membrane receptor modulators.
  • Reagent Antibody Development Service Generative AI-empowered antibody discovery and engineering service used to develop high-performance research reagents, validated through the project with BD (Becton, Dickinson and Company).
  • Pharma Antibody Discovery Partnerships and NewCo Cooperation Multi-year enterprise antibody discovery and NewCo cooperation engagements with multinational pharmaceutical companies that monetize Aureka's AuraIDE™ platform output via milestone-driven partnership deals.
  • Internal Cardiometabolic, Immunology, and CNS Antibody Pipeline Proprietary internal pipeline of eight differentiated antibody therapeutics targeting cardiovascular metabolism, immunology, and CNS disease areas, intended for out-licensing to larger pharma partners and clinical development (two projects targeted for clinical trials by end of 2026).

Quantifiable outcome

  • Drug discovery timeline reduced from months to weeks
  • +4 more outcomes

Companies that use Aureka Biotechnologies

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Aureka Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

Aureka Biotechnologies partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core ecosystem partner, strategic advisor, minor, moderate, flagship strategic customer and flagship ecosystem partner.

  • Biocom Californiacore ecosystem partnerGTM or Marketing Partner · 4 December 2025Aureka featured in Biocom California's Member Spotlight (December 4, 2025). Biocom is a California life-sciences industry association providing networking, partnering conferences (e.g., Global Life Science Partnering & Investor Conference), and member visibility.
  • Dr. David W. Shen (Founder & CEO, Propeller Bio)strategic advisorOthers · 6 August 2025Joined Aureka's Scientific Advisory Board (August 6, 2025). Dr. Shen brings experience in biopharmaceutical innovation, from scientific research to company building. He is Founder & CEO of Propeller Bio. His expertise will guide Aureka's mission to accelerate therapeutic discovery through AI and high-throughput biology.
  • ZymeworksminorGTM or Marketing Partner · 10 September 2024Co-presented in the ACRO Biosystems 'Building the Perfect Antibody-based Therapeutic' webinar (September 10, 2024) alongside Aureka Bio and ACRO Biosystems. Zymeworks presented on antibody engineering with AI-driven candidate selection optimization.
  • ACRO BiosystemsmoderateGTM or Marketing Partner · 10 September 2024Co-presented the 'Building the Perfect Antibody-based Therapeutic' webinar (September 10, 2024) with Aureka Bio and Zymeworks. ACRO Biosystems covered precision in antibody conjugation and ADC manufacturing tools. Also co-organized the ACROConnect Workshop at World ADC San Diego 2024.
  • BD (Becton, Dickinson and Company) / BD Biosciencesflagship strategic customerStrategic or Co-development Partner · 23 May 2024Announced project (May 23, 2024) with BD, a leading global medical technology company, to harness Aureka's generative AI-empowered antibody discovery and engineering platform to develop high-performance research reagents for scientific research.
  • NVIDIA (NVIDIA Inception)flagship ecosystem partnerTechnology or Integration · 5 December 2023Aureka joined NVIDIA Inception (announced December 4, 2023), a program that nurtures startups revolutionizing industries with AI. Benefits include access to advanced NVIDIA hardware and software, NVIDIA Deep Learning Institute credits, preferred pricing, and technological assistance to scale Aureka's AI-driven drug discovery efforts.
  • Dr. Peter M. Tessier (Albert M. Mattocks Professor, University of Michigan)strategic advisorOthers · 19 October 2023Joined Aureka Biotechnologies' Scientific Advisory Board (October 19, 2023). Dr. Tessier holds the Albert M. Mattocks Professorship in Pharmaceutical Sciences and Chemical Engineering at the University of Michigan and is internationally recognized for expertise in protein engineering, biopharmaceuticals, computational biology and drug discovery.

Scale indicators9 records

Recent moves5 records

Expansion highlights7 records

Aureka Biotechnologies competitors and assessment

Company assessment

Direct peers

  • BigHat Biosciences: BigHat Biosciences uses an AI-guided antibody design platform with high-throughput wet-lab characterization to engineer antibody candidates for pharma partners. Directly comparable in integrating machine learning with experimental data for next-generation antibody design.
  • Adagene: Adagene is an AI-driven antibody discovery and development company using its Dynamic Precision Therapeutics platform to engineer antibody candidates against difficult oncology targets. Overlaps with Aureka in AI-driven antibody discovery and function-first design philosophy.
  • Absci: Absci combines generative AI (zero-shot protein design) with high-throughput synthetic biology (soluency E. coli-based screening) to design and validate antibody therapeutics end-to-end. Closely parallel to Aureka's generative-AI-plus-wet-lab stack and pharma partnership GTM.
  • Generate Biomedicines: Generate Biomedicines is a generative AI biotech (founded by Flagship Pioneering) developing protein therapeutics de novo — directly paralleling Aureka's generative antibody design approach and pharma-partnered business model.
  • AbCellera Biologics: AbCellera operates a tech-bio platform for AI-driven antibody discovery, including its own wet-lab screening and a protein language model (like Aureka, it combines high-throughput biology with machine learning for therapeutic antibody generation). It is the most-cited comparable for Aureka's BD-and-pipeline business model.
  • Adimab: Adimab operates one of the most established antibody discovery platforms used by major pharma partners, with a focus on bispecifics and challenging targets. Although more traditional (less AI-native than Aureka), it is a direct competitor for the same pharma BD and bispecific discovery deals.

Broad incumbents

  • Insitro: Insitro applies machine learning to pharma discovery with a focus on data-driven biology and partnerships with large pharma (Genentech, Eli Lilly). Comparable in spirit to Aureka as a data + AI + biology platform pursuing pharma BD deals, though focused on small-molecule and target discovery rather than antibodies.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's protein-folding and AI capabilities to drug design. A broad incumbent whose capabilities overlap with Aureka's protein language model approach, with much greater capital and computational resources.

Emerging players

  • Xaira Therapeutics: Xaira Therapeutics is a well-funded AI drug discovery startup (launched in 2024 with $1B) applying foundation models to protein design and small-molecule discovery. Comparable to Aureka in generative biology focus, though broader in scope and deeper-pocketed.
  • Cradle Bio: Cradle uses generative AI for protein engineering, with applications spanning enzymes and therapeutics. Comparable to Aureka in its protein language model + iterative wet-lab learning approach, but with broader end-markets beyond antibodies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aureka Biotechnologies social profiles

Digital presence

Aureka Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aureka Biotechnologies leadership team

Management profile

Number of profiles

Profiles4 records

Aureka Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aureka Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aureka Biotechnologies

What does Aureka Biotechnologies do?

Aureka Biotechnologies commercializes an integrated AI-driven antibody drug design platform — AuraIDE™ — that combines high-throughput synthetic biology (autonomous yeast-based hypermutation), single-cell microfluidic functional screening, and a geometric-aware protein language model with deep reinforcement learning in a closed-loop Generate-Test-Learn-Optimize cycle. The platform is delivered to multinational pharmaceutical and biotech clients via enterprise antibody discovery partnerships, NewCo cooperation agreements, and custom service engagements (e.g., the BD Biosciences reagent development project), and also underpins an internal pipeline of eight proprietary antibody therapeutics across cardiometabolic, immunology, and CNS disease areas.

Is Aureka Biotechnologies a public or private company?

Aureka Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aureka Biotechnologies founded?

Aureka Biotechnologies was founded in 2023. It employs 11 to 50 people.

Where is Aureka Biotechnologies based?

Aureka Biotechnologies is headquartered in Laguna Hills, United States, in the North America region.

How does Aureka Biotechnologies make money?

Three revenue lines are on record. Pharma business development and NewCo cooperation deals are the primary driver. The others are internal pipeline licensing / asset out-licensing and reagent antibody discovery services.

Who are Aureka Biotechnologies's main competitors?

Direct peers on record are BigHat Biosciences, Adagene, Absci, Generate Biomedicines, AbCellera Biologics and Adimab. Broad incumbents are Insitro and Isomorphic Labs. Emerging players are Xaira Therapeutics and Cradle Bio.

Does Aureka Biotechnologies have an API?

No public API is recorded for Aureka Biotechnologies.

What industry is Aureka Biotechnologies in?

Aureka Biotechnologies's product category is AI-driven antibody therapeutics discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OcbjBiotech Startup Aureka Raises $100M Series BAureka Biotechnologies raised $100 million in a Series B round, bringing total funding to nearly $200 million. The company will use the funds to advance its AI drug-discovery platform toward Phase 1 clinical trials and expand laboratory operations. It plans to generate revenue through its own therapeutics and pharmaceutical partnerships.AijournAureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental ResultAureka Biotechnologies announced on Aug. 26, 2026 that its in-house antibody design model AuraIDE won first place in Challenge 1 of AIntibody, the first international AI antibody design competition, with results published in Nature Biotechnology. The winning antibody showed a KinExA affinity of 94.7pM, roughly 2,000-fold higher than the parental antibody, outperforming the best experimental clone at 113pM.PR NewswireNature Biotechnology | Aureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental ResultAureka Biotechnologies announced that its in-house antibody design model, AuraIDE, entered as AuraBind, won first place in Challenge 1 of the AIntibody competition, an international AI antibody design benchmark published in Nature Biotechnology. The blinded benchmark validated every entry with independent wet-lab experiments under identical conditions. The company cited AuraBind in the published results.PR Newswire APACAureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental Result - PR Newswire APACAureka Biotechnologies announced that its in-house antibody design model, AuraIDE, won first place in Challenge 1 of AIntibody, the first international AI antibody design competition, with results published in Nature Biotechnology. AuraIDE's designed antibody reached 94.7pM affinity by KinExA, roughly 2,000-fold over the parental antibody, while 29 organizations submitted 511 antibodies.TalkMarketsInvestment Opportunities Emerging in the Global Drug Discovery Platforms MarketThe global drug discovery platforms market is projected to grow from USD 3.9 billion in 2026 to USD 10.5 billion by 2033, driven by the integration of artificial intelligence and advanced computing into research workflows. Key industry players including Amazon Web Services, Tata Consultancy Services, Aureka Biotechnologies, and Anthropic are launching specialized AI tools and platforms to accelerate drug candidate identification and validation.AI CERTsAureka Biotechnologies Raises $100M to Advance AI-Driven Drug Discovery and Why AI Training MattersAureka Biotechnologies has raised $100 million in funding to advance its AI-driven drug discovery platform, specifically targeting the training of next-generation biological foundation models and Lab-in-the-Loop infrastructure. This investment supports the company's closed-loop approach, which integrates AI hypothesis generation with experimental validation to refine biomolecular structure prediction and de novo molecular design. The development highlights a broader industry shift toward embedding AI as a core component of the scientific research process in biotechnology.pharmaphorumWhich biotechs have raised new VC financing this week?Vaderis Therapeutics raised $152 million in second-round financing to fund its phase 3 trial of engasertib for hereditary haemorrhagic telangiectasia. Aureka Biotechnologies closed a $100 million Series B, Epicrispr raised $90 million, Infinimmune added $75 million, and Boulevard Bio emerged with $65 million.Pulse 2.0Aureka Biotechnologies Raises $100 Million Series B To Build Biological World Model For Drug DiscoveryAureka Biotechnologies has raised $100 million in Series B financing, exclusively funded by Granite Asia for the first tranche, bringing its total funding to nearly $200 million. The company plans to use the capital to advance its biological foundation models and expand its Lab-in-the-Loop experimental feedback platform for AI-native drug discovery.Tech TimesAureka Open-Sourced Antibody AI That Beats AlphaFold 3; Closes $100M Drug Discovery RoundAureka Biotechnologies announced it closed a $100 million Series B funding round, supporting its development of an open-source antibody AI model called OpenDDE, which outperforms AlphaFold 3 in benchmarks. The company emphasizes its Lab-in-the-Loop infrastructure as its competitive advantage, integrating wet-lab experiments with AI training.BioSpaceAureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug DiscoveryAureka Biotechnologies closed a US$100 million Series B financing led by Granite Asia, bringing its total capital raised to nearly US$200 million. The company intends to use the funds to advance its biological foundation models and enhance its 'Lab-in-the-Loop' infrastructure for AI-driven drug discovery. This investment supports Aureka's strategy to transition from efficient computational design to simulating complex biological systems for antibody development.